Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,253 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo First Clear all
Completed Phase 2 Interventional Results available

Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

NCT05421598
View directory record Official record
Conditions
Asthma
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
La Jolla, California • Los Angeles, California • San Jose, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Not applicable Interventional Results available

Nicotine Withdrawal Symptoms and Smoking Relapse

NCT01511614
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Transcranial Direct Current Stimulation, sham, Nicotine patch, Placebo patch, Varenicline Pill, Placebo pill, Motivational Interviewing
Device · Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

NCT00790036
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Everolimus, Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
34
States / cities
Chandler, Arizona • Fayetteville, Arkansas • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

NCT05711719
View directory record Official record
Conditions
Metabolic Syndrome, Coronary Microvascular Dysfunction
Interventions
Vericiguat, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
35 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

MT10109L in the Treatment of Glabellar Lines

NCT03795922
View directory record Official record
Conditions
Glabellar Lines
Interventions
MT10109L, Placebo
Drug
Lead sponsor
Medy-Tox
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
9
States / cities
Scottsdale, Arizona • Solana Beach, California • Bradenton, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 18, 2026, 9:23 AM EDT
Active, not recruiting Phase 2 Interventional

PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

NCT06853912
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), PTSD
Interventions
Psilocybin 25 mg, Maltodextrin (Placebo)
Drug
Lead sponsor
Nathan Brashares Sackett
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

NCT00526630
View directory record Official record
Conditions
Parkinson's Disease, Gait Impairment
Interventions
Methylphenidate (MPD), Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
35 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion

NCT03274453
View directory record Official record
Conditions
Spinal Fusion
Interventions
Ketamine, Saline
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 18, 2026, 9:23 AM EDT
Recruiting Phase 4 Interventional

Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

NCT03642028
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders, Stress Disorders, Posttraumatic
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Long Beach, California • San Francisco, California • Salisbury, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Antidepressant Medication Plus Donepezil for Treating Late-life Depression

NCT00177671
View directory record Official record
Conditions
Depression, Dementia
Interventions
Escitalopram, Donepezil, Venlafaxine, Placebo, Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Post-operative Urinary Retention

NCT02486653
View directory record Official record
Conditions
Urinary Retention, Urinary Tract Infections
Interventions
Tamsulosin, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

NCT00069095
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg, Placebo for bevacizumab 7.5 mg/kg, Oxaliplatin 85 mg/m^2, Leucovorin 200 mg/m^2, Fluorouracil 400 mg/m^2, Bevacizumab 5 mg/kg, Placebo for bevacizumab 5 mg/kg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
49
States / cities
Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Neuroscience-Informed Treatment Development for Adolescent Alcohol Use

NCT03238300
View directory record Official record
Conditions
Alcohol Drinking, Control
Interventions
N-Acetylcysteine, Placebo Oral Capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
15 Years to 19 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 18, 2026, 9:23 AM EDT
Recruiting Phase 2 Interventional

Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism

NCT04060030
View directory record Official record
Conditions
Autism Spectrum Disorder, Language Disorders
Interventions
Levoleucovorin Calcium, Placebo
Drug · Other
Lead sponsor
Southwest Autism Research & Resource Center
Other
Eligibility
30 Months to 60 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 18, 2026, 9:23 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

NCT06539507
View directory record Official record
Conditions
Netherton Syndrome
Interventions
BCX17725, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
5
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Not applicable Interventional Results available

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

NCT01117454
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
Flecainide Acetate, Placebo, Beta blocker
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
5 Years to 99 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 18, 2026, 9:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Obstetric Life Support, a Curriculum to Effectively Resuscitate Pregnant Patients Experiencing Cardiac Arrest.

NCT05355519
View directory record Official record
Conditions
Cardiac Arrest, Pregnancy Related
Interventions
Electronic curriculum and instructor-led course, then placebo, Placebo, then electronic curriculum and instructor-led course
Other
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 18, 2026, 9:23 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Intranasal Oxytocin Intervention for Caregivers to Persons With Dementia

NCT06364228
View directory record Official record
Conditions
Stress
Interventions
Placebo, Oxytocin Intranasal Spray 12 International Unit (12IU), Oxytocin Intranasal Spray 24 International Unit (24IU), Functional MRI
Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma

NCT01160380
View directory record Official record
Conditions
Fatigue, Multiple Myeloma
Interventions
armodafinil, Placebo
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Anaheim, California • Newport Beach, California • West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 18, 2026, 9:23 AM EDT
Terminated Phase 3 Interventional Results available

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

NCT00089141
View directory record Official record
Conditions
Cancer
Interventions
mycophenolate mofetil, placebo
Drug
Lead sponsor
Martin, Paul
Other
Eligibility
4 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
15
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 18, 2026, 9:23 AM EDT
Terminated Phase 3 Interventional Results available

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

NCT04478266
View directory record Official record
Conditions
Breast Cancer
Interventions
Amcenestrant-matching placebo, SAR439859, Palbociclib, Letrozole, Goserelin, Letrozole-matching placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
45
States / cities
Daphne, Alabama • Glendale, Arizona • Tucson, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults

NCT07225413
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Rhodiola rosea (low dose), Rhodiola rosea (high dose), Placebo capsules
Dietary Supplement
Lead sponsor
Jacksonville State University
Other
Eligibility
18 Weeks to 40 Weeks
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Jacksonville, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 18, 2026, 9:23 AM EDT
Completed Phase 1 Interventional Results available

Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study

NCT01393782
View directory record Official record
Conditions
Septic Shock
Interventions
Angiotensin II
Drug
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 18, 2026, 9:23 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

NCT03775486
View directory record Official record
Conditions
Non-small Cell Lung Cancer NSCLC
Interventions
Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 18, 2026, 9:23 AM EDT